All In Biotech

Drug Trial Radar · NCT05813925

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 331 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

331

Actual

Start

Apr 3, 2023

Primary completion

Jan 17, 2025

Study completion Mar 7, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

Conditions

  • Obesity or Overweight

Interventions

  • CagrilintideDrug

    Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

  • SemaglutideDrug

    Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks

  • Placebo SemaglutideDrug

    Participants will receive placebo matched to semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative Change in Body WeightTime frame: From baseline (week 0) to end of treatment (week 68)

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology

    Aichi, Japan

  • The University of Tokyo Hospital, Diabetes and Metabolic

    Bunkyo-ku, Tokyo, Japan

  • Akaicho Clinic

    Chiba-shi, Chiba, Japan

  • Suidoubashi Medical Clinic_Internal Medicine

    Chiyoda-ku, Tokyo, Japan

  • The Institute of Medical Science, Asahi Life Foundation_Internal Medicine

    Chuo-ku, Tokyo, Japan

  • The Institute of Medical Science, Asahi Life Foundation

    Chuo-ku, Tokyo, Japan

  • Okabe Clinic

    Chuo-ku, Tokyo, Japan

  • Kawada Clinic

    Gunma, Japan

  • Naka Kinen Clinic_Internal medicine

    Ibaraki, Japan

  • Naka Kinen Clinic

    Ibaraki, Japan

  • Iwate Medical University Uchimaru Medical Center, Division of Diabetes and Metabolism and Endocrine medicine

    Numakunai, Japan

  • Osaka NISHI-UMEDA Clinic_Internal Medicine

    Osaka, Japan

  • Osaka NISHI-UMEDA Clinic

    Osaka, Japan

  • Shinsapporo Seiryou Hospital, General Clinical Department

    Sapporo-shi, Hokkaido, Japan

  • Shinden Higashi Clinic_Internal medicine

    Sendai-shi, Miyagi, Japan

  • Shinden Higashi Clinic

    Sendai-shi, Miyagi, Japan

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, Japan

  • Fukuwa Clinic_Internal Medicine

    Tokyo, Japan

  • Fukuwa Clinic

    Tokyo, Japan

  • ToCROM Clinic_Internal Medicine

    Tokyo, Japan

  • Minamino Cardiovascular Hospital_Cardiovascular medicine

    Tokyo, Japan

  • Seino Internal Medicine Clinic_Internal medicine

    Koriyama-shi, Fukushima, Fukushima, Japan, Japan

  • Tsuruma Kaneshiro Diabetes Clinic_Internal medicine

    Yamato-shi, Kanagawa, Japan

  • Tsuruma Kaneshiro Diabetes Clinic

    Yamato-shi, Kanagawa, Japan

  • Heiwadai Hospital_Internal Medicine

    Miyazaki, Miyazaki, Japan

  • OCROM Clinic_Internal medicine

    Suita-shi, Osaka, Japan

  • Yao Tokushukai General Hospital_Cardiovascular division

    Yao-shi, Osaka, Japan

  • National Taiwan University Hospital_main

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.